Pink Sheet reports on Aranesp and Procrit concerns
Matthew Arnold
July 01 2007
Members of the FDA’s Oncologic Drugs Advisory Committee expressed concerns at a May meeting that DTC advertising of Amgen’s Aranesp ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Your message:
The e-mail address(es) that you supply to use this service will only be used to send the requested article.